ATP1A3 and Global developmental delay: Developmental delay was evident in 69/140 (49%) patients, being severe in 36 patients with neurotransmitter defects (SLC6A3, TH, DHPR, DDC) and in GNAO1‐, FOXG1‐, and ATP1A3‐related HMDs.